Recombinant Vaccine CDMO Market (2026 - 2033)

Recombinant Vaccine CDMO Market Summary

The global recombinant vaccine CDMO market size was valued at USD 5.6 billion in 2025 and is projected to grow from USD 6.1 billion in 2026 to USD 12.4 billion by 2033, at a CAGR of 10.5% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 43.8% in 2025. Market growth is driven by increasing demand for recombinant protein vaccines, expansion of vaccine development pipelines, and growing outsourcing of vaccine development and manufacturing activities.

Moreover, the need for specialized capabilities in recombinant antigen expression, upstream and downstream processing, formulation, and fill-finish services is increasing the demand for CDMO services. Technological advancements in recombinant expression systems, cell line development, process optimization, automation, and analytical testing are improving manufacturing efficiency, product consistency, and scalability.

Furthermore, the vaccine industry has witnessed continued growth in recent years, supported by increasing vaccine development activities and advances in recombinant protein technologies. The growing number of recombinant vaccine candidates across infectious disease indications is increasing demand for specialized development and manufacturing capabilities. These products require controlled antigen expression, purification, formulation, analytical characterization, and GMP-compliant manufacturing processes. Thus, the expansion of recombinant vaccine development pipelines is expected to increase demand for specialized CDMO services in the coming years.

In addition, several pharmaceutical and biotechnology companies are increasingly outsourcing recombinant vaccine development and manufacturing activities to specialized CDMOs due to the technical expertise, specialized infrastructure, and capital requirements associated with in-house production. CDMOs provide process development, expression system optimization, scale-up, GMP manufacturing, analytical testing, formulation, and fill-finish services. This approach enables vaccine developers to access specialized manufacturing capabilities while reducing the need to establish dedicated production facilities. The trend is particularly relevant among emerging biotechnology companies progressing recombinant vaccine candidates through clinical development and requiring flexible manufacturing capacity.

Market Dynamics

Impact of U.S. Tariffs on the Recombinant Vaccine CDMO market

U.S. tariffs can have an indirect impact on the recombinant vaccine CDMO market by increasing costs across vaccine manufacturing supply chains. Recombinant vaccine CDMO operations may require imported laboratory equipment, single-use manufacturing components, filtration systems, chromatography materials, specialized consumables, and other production inputs. Higher import costs for these materials can increase manufacturing and process development expenses, particularly for CDMOs with significant exposure to international suppliers. Service providers may respond through supplier diversification, inventory planning, alternative sourcing, and adjustments to procurement strategies.

Tariff-related cost increases may also influence the location of vaccine development and manufacturing activities. Companies seeking to reduce exposure to import duties and supply disruptions may favor CDMOs with established U.S. manufacturing infrastructure or diversified regional supply networks. However, service providers with limited supplier options may face greater cost pressure and longer procurement cycles. Global CDMOs may therefore increase regional sourcing, qualify alternative suppliers, and expand localized manufacturing capabilities. Overall, tariff-related changes could contribute to greater supply-chain diversification and regionalization within recombinant vaccine development and manufacturing.

Technological Advancements

Technological advancements are reshaping the recombinant vaccine CDMO market by improving process efficiency, manufacturing consistency, scalability, and analytical control across vaccine development and production. Automation and high-throughput process development platforms are streamlining recombinant antigen production, purification, formulation, and quality testing while reducing manual intervention. Advances in recombinant expression systems, including microbial and mammalian platforms, are improving antigen yield and supporting process optimization. Moreover, chromatography systems, membrane-based purification, single-use technologies, and automated process control are enabling more efficient downstream processing and GMP manufacturing. Analytical technologies such as high-performance liquid chromatography, mass spectrometry, polymerase chain reaction, and next-generation sequencing are also supporting characterization of recombinant antigens, process-related impurities, residual host-cell DNA, and other quality attributes.

Furthermore, artificial intelligence, machine learning, and digital process monitoring are being adopted to support process development, manufacturing data analysis, predictive maintenance, and quality control. Digitalization can facilitate real-time monitoring of critical process parameters and improve data management across development and manufacturing workflows. Advances in continuous manufacturing and process analytical technology are also creating opportunities to improve process control and production efficiency. As recombinant vaccine pipelines expand, these technologies are becoming increasingly important for developing scalable processes, maintaining product consistency, and meeting evolving GMP and regulatory requirements. Thus, technological advancements are expected to support market growth over the forecast period.

Pricing Model Analysis

In the recombinant vaccine CDMO market, pricing models are important for managing differences in project complexity, development stage, manufacturing requirements, batch size, and client requirements. Milestone-based pricing links payments to defined project stages, such as expression system development, process development, technology transfer, GMP manufacturing, analytical testing, and clinical batch production. This model can be suitable for recombinant vaccine programs that progress through multiple development phases and require payments according to completed deliverables.

Fixed-fee pricing can provide greater cost predictability for defined services, including analytical testing, formulation development, process characterization, and specific manufacturing activities with established scope and requirements. Furthermore, cost-plus pricing may be applied to projects involving variable manufacturing inputs, specialized materials, additional testing, or changes in production requirements. Time-and-materials pricing can support early-stage development activities where the scope may change as process optimization progresses. In addition, long-term contractual arrangements may be used by vaccine developers requiring recurring manufacturing, testing, or development services across multiple batches. These pricing approaches provide flexibility according to project scope and development stage while enabling CDMOs to manage variable technical and manufacturing requirements.

Market Concentration & Characteristics

The recombinant vaccine CDMO Market is at a medium growth stage, while the pace of market growth is accelerating. The market is characterized by increasing outsourcing of vaccine development and manufacturing, service expansion, technological advancements, regulatory requirements, strategic collaborations, and regional capacity expansion.

The market is witnessing continuous innovation through advances in recombinant expression systems, process development, purification technologies, automation, and analytical characterization. High-throughput screening, automated bioprocessing, single-use technologies, process analytical technology, and advanced chromatography systems are improving production efficiency and process control. Developments in microbial and mammalian expression platforms are also supporting higher antigen yields and improved scalability.

Regulatory requirements established by agencies such as the FDA, EMA, and other national regulatory authorities have a significant impact on recombinant vaccine development and manufacturing. Requirements related to GMP production, process validation, quality control, product characterization, sterility, purity, potency, and consistency influence CDMO selection and service requirements. Furthermore, regulatory expectations for manufacturing process control and analytical characterization increase the need for CDMOs with validated facilities, quality systems, and regulatory expertise.

Mergers and acquisitions contribute to market development by enabling CDMOs to expand manufacturing capacity, technical capabilities, geographic presence, and service portfolios. Strategic acquisitions within the broader biologics and vaccine manufacturing sector can provide access to specialized facilities, process technologies, analytical capabilities, and established client relationships. M&A activity is expected to remain relevant as CDMOs seek to strengthen integrated recombinant vaccine development and manufacturing capabilities.

Increasing demand for recombinant vaccine outsourcing is encouraging CDMOs to expand their service portfolios across the development and manufacturing lifecycle. Services include expression system development, cell or microbial culture, upstream and downstream process development, purification, formulation, analytical testing, technology transfer, GMP manufacturing, fill-finish, and stability studies. Moreover, CDMOs are developing integrated service models that support vaccine candidates from early development through clinical and commercial manufacturing, addressing the requirements of both emerging biotechnology companies and established pharmaceutical manufacturers.

The market is experiencing regional expansion across North America, Europe, and the Asia Pacific. North America maintains a strong position due to its established biopharmaceutical sector, advanced manufacturing infrastructure, and extensive regulatory framework. Europe also has a developed vaccine manufacturing ecosystem supported by established pharmaceutical and biotechnology companies. Furthermore, the Asia Pacific is expanding its recombinant vaccine manufacturing capabilities due to increasing biopharmaceutical production, growing CDMO capacity, improving manufacturing infrastructure, and expanding participation of regional pharmaceutical and biotechnology companies.

Analyst Perspective

The recombinant vaccine CDMO market is becoming increasingly important as recombinant vaccine candidates progress through complex development, scale-up, and commercial manufacturing pathways. Demand is shifting toward integrated services covering expression system development, process optimization, antigen purification, formulation, analytical characterization, GMP manufacturing, and fill-finish. Vaccine developers are prioritizing outsourcing due to specialized infrastructure requirements, technical expertise, regulatory documentation, manufacturing scalability, and the need to shorten development timelines. Growth is supported by expanding recombinant vaccine pipelines, increasing vaccine manufacturing capacity, and stricter requirements for product quality, consistency, and process control. The market is witnessing a greater preference for CDMO partners capable of supporting programs from early development through commercial manufacturing, particularly for technically complex recombinant protein and viral vector vaccines.

Vaccine Insights

The recombinant protein/subunit vaccines segment led the market with the largest revenue share of 47.3% in 2025. The segment growth is driven by the established use of recombinant proteins as vaccine antigens and the increasing demand for scalable manufacturing capabilities. Recombinant protein vaccines require specialized expression systems, antigen purification, formulation, analytical characterization, and GMP manufacturing, creating sustained demand for CDMO services. Moreover, increasing vaccine development activities and the need for flexible manufacturing capacity are supporting the outsourcing of recombinant protein vaccine production.

On the other hand, the recombinant viral vector vaccines segment is expected to grow at the fastest CAGR over the forecast period. The segment growth is driven by increasing research into recombinant viral vectors as vaccine delivery platforms and advances in genetic engineering technologies. In addition, the development of novel vaccine candidates is increasing demand for specialized upstream processing, downstream purification, analytical testing, and GMP manufacturing capabilities. The technical complexity associated with viral vector production is also encouraging developers to outsource manufacturing activities to specialized CDMOs.

Service Insights

The contract manufacturing segment led the market with the largest revenue share of 47.5% in 2025 and is estimated to grow at the fastest CAGR over the forecast period. The segment growth is driven by increasing demand for scalable GMP manufacturing of recombinant vaccine candidates and the high infrastructure requirements associated with vaccine production. CDMOs provide specialized capabilities across upstream processing, downstream purification, formulation, quality control, and fill-finish manufacturing. Moreover, pharmaceutical and biotechnology companies are increasingly outsourcing manufacturing activities to access specialized facilities and production expertise without establishing extensive internal infrastructure.

Meanwhile, the contract development segment is expected to grow significantly over the forecast period. The segment growth is driven by increasing demand for expression system development, process optimization, formulation development, analytical method development, and technology transfer. In addition, emerging biotechnology companies are progressing recombinant vaccine candidates through preclinical and clinical development, increasing the need for specialized process development support. These factors are expected to increase demand for contract development services throughout the forecast period.

Expression Platform Insights

The mammalian cell expression segment led the market with the largest revenue share of 41.2% in 2025. The segment growth is driven by the ability of mammalian systems to produce complex recombinant proteins with appropriate structural characteristics and post-translational modifications. The increasing development of recombinant antigens requiring complex protein structures is supporting demand for mammalian expression capabilities. Moreover, advances in cell line development, bioreactor systems, and process optimization are improving the scalability and efficiency of mammalian-based recombinant vaccine manufacturing.

The plant-based expression segment is expected to grow at the fastest CAGR over the forecast period, driven by increasing research into alternative recombinant antigen production platforms. Plant-based systems can support scalable protein production and may provide advantages related to manufacturing flexibility and production costs. In addition, advances in genetic engineering and transient expression technologies are improving antigen production capabilities. Growing research into alternative vaccine manufacturing platforms is expected to create additional opportunities for CDMOs offering specialized plant-based expression services.

Workflow Insights

The commercial segment led the market with the largest revenue share of 62.3% in 2025 and is expected to grow at the fastest CAGR over the forecast period. The segment growth is due to increasing demand for commercial-scale manufacturing of recombinant vaccines and the requirement for consistent GMP production. Commercial manufacturing involves process validation, scale-up, quality control, batch release, stability testing, and regulatory documentation, creating substantial demand for specialized CDMO capabilities. Moreover, vaccine developers increasingly require flexible manufacturing capacity to support commercial production and market expansion.

The clinical segment is expected to grow significantly over the forecast period. The segment growth is driven by the increasing number of recombinant vaccine candidates progressing through preclinical and clinical development. Clinical-stage programs require process development, technology transfer, clinical batch manufacturing, analytical testing, and stability studies before advancing to subsequent development stages. Increasing outsourcing among biotechnology companies with limited internal manufacturing infrastructure is further supporting demand for clinical-stage CDMO services.

Therapeutic Area Insights

The infectious diseases segment led the market with the largest revenue share of 69.5% in 2025. The growth is attributed to the primary application of recombinant vaccine technologies in the prevention of infectious diseases. Increasing research into recombinant protein antigens and advances in vaccine development platforms are creating demand for specialized CDMO capabilities. Moreover, the development of vaccines targeting bacterial, viral, and parasitic infections requires scalable antigen production, purification, formulation, analytical testing, and GMP manufacturing, supporting segment growth.

The oncology segment is expected to grow at the fastest CAGR over the forecast period, fueled by increasing research into therapeutic cancer vaccines and recombinant antigen technologies. The development of personalized and targeted cancer vaccine candidates is increasing the demand for specialized development and manufacturing capabilities. In addition, advances in recombinant protein engineering, antigen design, and immune-response technologies are supporting research into oncology vaccine platforms. These factors are expected to create additional demand for specialized CDMO services over the forecast period.

End-use Insights

The pharmaceutical companies segment led the market with the largest revenue share of 54.5% in 2025. This segment is driven by the increasing development and commercialization of recombinant vaccines and the need for specialized manufacturing capabilities. Pharmaceutical companies require CDMO support across process development, technology transfer, GMP manufacturing, analytical testing, formulation, and fill-finish operations. Furthermore, outsourcing enables pharmaceutical companies to access specialized facilities and manufacturing expertise while managing production requirements across different development and commercial stages.

The biotechnology companies segment is expected to witness the fastest growth over the forecast period. The increasing number of biotechnology companies developing recombinant vaccine candidates is creating demand for outsourced development and manufacturing services. These companies often require external support for expression system development, process optimization, clinical batch manufacturing, and regulatory documentation. In addition, limited internal manufacturing infrastructure and the need to accelerate development timelines are encouraging biotechnology companies to engage specialized CDMOs, supporting segment growth.

Regional Insights

The North America recombinant vaccine CDMO market accounted for the largest market share of 43.8% in 2025, supported by its established pharmaceutical and biotechnology industry, advanced biologics manufacturing infrastructure, and strong vaccine development capabilities. The region’s concentration of major CDMOs, extensive clinical research activities, and established GMP manufacturing facilities is supporting demand for recombinant vaccine development and production services.

U.S. Recombinant Vaccine CDMO Market Trends

The recombinant vaccine CDMO market in the U.S. is driven by its large pharmaceutical and biotechnology sector, advanced biomanufacturing infrastructure, and established regulatory framework. Moreover, the increasing development of recombinant vaccine candidates and demand for flexible GMP manufacturing capacity are supporting outsourcing to specialized CDMOs. The presence of established vaccine developers and contract manufacturers is further contributing to market growth.

Europe Recombinant Vaccine CDMO Market Trends

The recombinant vaccine CDMO market in Europe is experiencing growth due to its established pharmaceutical manufacturing industry, advanced biotechnology capabilities, and strong regulatory framework. Moreover, increasing demand for localized vaccine manufacturing and expansion of biologics production are supporting CDMO services. The region’s focus on manufacturing quality, process validation, and regulatory compliance is further increasing demand for specialized recombinant vaccine development and manufacturing capabilities.

The Germany recombinant vaccine CDMO market is anticipated to grow significantly over the forecast period due to its strong pharmaceutical and biotechnology manufacturing base. The country’s advanced bioprocessing infrastructure, focus on research and development, and established quality systems support recombinant vaccine manufacturing activities. Moreover, increasing demand for GMP-compliant production and specialized biologics manufacturing services is contributing to market expansion.

The recombinant vaccine CDMO market in the UK held a significant share in 2025. The country’s market growth is supported by its established biotechnology sector, strong academic research base, and government support for life sciences development. Moreover, increasing vaccine research activities and the presence of specialized biologics manufacturing facilities are creating demand for recombinant vaccine development, analytical, and manufacturing services.

Asia Pacific Recombinant Vaccine CDMO Market Trends

The recombinant vaccine CDMO market in the Asia Pacific is projected to grow at the highest CAGR over the forecast period. The growth of the market is mainly due to increasing biopharmaceutical manufacturing, expanding vaccine production capabilities, improving biotechnology infrastructure, and government initiatives supporting domestic pharmaceutical production. Moreover, competitive manufacturing costs and increasing outsourcing by global pharmaceutical companies are supporting CDMO expansion across the region.

The China recombinant vaccine CDMO market is expected to grow over the forecast period. The growth is driven by the expansion of domestic vaccine manufacturing, increasing biotechnology research, and government initiatives supporting biologics development. Moreover, efforts to strengthen domestic biopharmaceutical manufacturing capabilities and improve production infrastructure are boosting the demand for recombinant vaccine development and manufacturing services in the country.

The recombinant vaccine CDMO market in Japan is witnessing significant growth over the forecast period. The growth is supported by the country’s established pharmaceutical industry, advanced biotechnology capabilities, and increasing research into innovative vaccine technologies. Moreover, strong quality standards, advanced manufacturing infrastructure, and regulatory capabilities are supporting the development of specialized recombinant vaccine CDMO services.

The India recombinant vaccine CDMO market is witnessing considerable growth due to the country’s expanding pharmaceutical and contract manufacturing sector, established vaccine production capabilities, and competitive biologics manufacturing environment. Moreover, government initiatives supporting biotechnology research, domestic vaccine production, and pharmaceutical manufacturing are increasing CDMO opportunities. Growing participation of biotechnology companies in recombinant vaccine development is further supporting market expansion.

Latin America Recombinant Vaccine CDMO Market Trends

The recombinant vaccine CDMO market in Latin America is gaining traction as pharmaceutical manufacturing, vaccine production, biotechnology research, and biologics development activities expand across the region. Demand is increasing for specialized development, analytical, and manufacturing services as local manufacturers strengthen production capabilities and align with international GMP standards. Brazil, Mexico, and Argentina remain key contributors due to their established pharmaceutical industries and expanding biotechnology capabilities.

The Brazil recombinant vaccine CDMO market expects a lucrative opportunity within Latin America due to its established pharmaceutical manufacturing base, vaccine production capabilities, and expanding biotechnology sector. The region is supported by increasing demand for local manufacturing capabilities and improvements in biologics production infrastructure. Moreover, public-sector healthcare programs and pharmaceutical manufacturing initiatives are supporting demand for specialized vaccine development and manufacturing services.

Middle East & Africa Recombinant Vaccine CDMO Market Trends

The recombinant vaccine CDMO market in the Middle East & Africa is gradually expanding, driven by pharmaceutical localization, healthcare infrastructure development, vaccine supply initiatives, and increasing interest in biotechnology manufacturing. Countries such as the UAE, Saudi Arabia, and South Africa are strengthening domestic pharmaceutical capabilities and regulatory frameworks. These developments are creating opportunities for GMP-compliant recombinant vaccine development, manufacturing, analytical testing, and fill-finish services.

The UAE recombinant vaccine CDMO market is emerging as a strategic opportunity within the Middle East due to its focus on healthcare innovation, pharmaceutical localization, and life sciences infrastructure. The country’s position as a regional healthcare and logistics hub supports opportunities for pharmaceutical manufacturing and outsourcing services. Moreover, government initiatives supporting biotechnology, healthcare diversification, and domestic pharmaceutical capabilities are creating opportunities for recombinant vaccine CDMO services, although specialized manufacturing capacity remains at an earlier development stage.

Key Recombinant Vaccine CDMO Company Insights

Market players are undertaking various strategic initiatives, such as the launch of new product innovations, collaborations, partnerships, and mergers & acquisitions, to strengthen their service offering and provide a competitive advantage. For instance, in April 2025, FUJIFILM Biotechnologies announced a 10-year manufacturing supply agreement valued at more than USD 3 billion with Regeneron Pharmaceuticals for U.S.-based biologics production at its Holly Springs, North Carolina facility. The agreement expands large-scale manufacturing capacity and strengthens the company’s broader biologics and vaccine CDMO infrastructure.

Key Recombinant Vaccine CDMO Companies:

The following key companies have been profiled for this study on the recombinant vaccine CDMO market.

• FUJIFILM Biotechnologies

• WuXi Biologics

• IDT Biologika

• Lonza

• Thermo Fisher Scientific (Patheon)

• AGC Biologics

• KBI Biopharma

• Ajinomoto Bio-Pharma Services

• Northway Biotech

• Batavia Biosciences

• Recipharm

• 3P Biopharmaceuticals

• Biofabri

• Biological E. Limited

• SK bioscience

Competitive Benchmarking

Recent Developments:

• In March 2026, IDT Biologika and SK bioscience signed an agreement for the contract development and manufacturing of the drug product for MSD’s Zaire Ebola vaccine using an updated manufacturing process. SK bioscience will produce the drug substance, while IDT will undertake drug product development and manufacturing, strengthening their integrated vaccine CDMO capabilities.

• In September 2025, Thermo Fisher Scientific (Patheon) entered into a 15-year commercial manufacturing and supply agreement with Vaxcyte. Patheon will formulate, fill, inspect, package, label, test, manufacture, and supply Vaxcyte’s drug product at its Greenville, North Carolina facility, strengthening its long-term vaccine manufacturing capacity.

• In June 2025, WuXi Biologics announced a strategic collaboration with Virogen Biotechnology to provide technology transfer, process validation, and commercial manufacturing of drug substance and drug product for Virogen’s VG712 program. The agreement expands WuXi Biologics’ integrated development and manufacturing services for complex biologics.

Recombinant Vaccine CDMO Market Report Scope

Global Recombinant Vaccine CDMO Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global recombinant vaccine CDMO market report based on vaccine, service, expression platform, workflow, therapeutic area, end-use, and region:

• Vaccine Outlook (Revenue, USD Billion, 2021 - 2033)

  • Recombinant Protein/Subunit Vaccines

  • Virus-Like Particle (VLP) Vaccines

  • Recombinant Viral Vector Vaccines

  • Recombinant DNA/mRNA-enabled Vaccines

  • Others

• Service Outlook (Revenue, USD Billion, 2021 - 2033)

  • Contract Development

    • Cell Line Development

    • Process Development & Optimization

    • Analytical Testing & Method Validation

    • Scale-up & Tech Transfer

  • Contract Manufacturing

    • API Manufacturing

    • Finished Drug Products Manufacturing

  • Packaging and Labeling

  • Regulatory Affairs

  • Others

• Expression Platform Outlook (Revenue, USD Billion, 2021 - 2033)

  • Mammalian Cell Expression

  • Microbial Expression

  • Cell-Based Expression

  • Plant-Based Expression

  • Others

• Workflow (Revenue, USD Billion, 2021 - 2033)

  • Clinical

  • Commercial

• Therapeutic Area (Revenue, USD Billion, 2021 - 2033)

  • Infectious Diseases

  • Oncology

  • Neurological Disorders

  • Other Applications

• End-use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Pharmaceutical Companies

  • Biotechnology Companies

  • Academic and Research Institutions

  • Others

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

    • Oman

    • Qatar

Research Methodology

The recombinant vaccineCDMOmarketfigures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing—reconciling supply-side and demand-side estimates—and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with eachrecombinant vaccine CDMOsegment quantified using the revenue-capture definitions in the table below.

Segment Definition

Estimation Model

Delivered Customizations

This report has been delivered with the following In-depth customizations